Public consultationshttps://www.ema.europa.eu/en/homepagePublic consultationsen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 12:13:52 +0200Fri, 05 Jul 2024 09:17:56 +0200Draft VICH GL23 Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing - Revision 2https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl23-studies-evaluate-safety-residues-veterinary-drugs-human-food-genotoxicity-testing-revision-2_en.pdfDraft VICH GL23 Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing - Revision 2https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl23-studies-evaluate-safety-residues-veterinary-drugs-human-food-genotoxicity-testing-revision-2_en.pdfFri, 05 Jul 2024 09:17:56 +0200Public consultationsConcept paper on the need for revision of the guideline on clinical investigation of medicinal products for the treatment of psoriatic arthritishttps://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-psoriatic-arthritis_en.pdfConcept paper on the need for revision of the guideline on clinical investigation of medicinal products for the treatment of psoriatic arthritishttps://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-psoriatic-arthritis_en.pdfMon, 01 Jul 2024 08:00:00 +0200Public consultationsDraft guideline on the conduct of efficacy studies for intramammary products for use in cattlehttps://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-efficacy-studies-intramammary-products-use-cattle_en.pdf-1Draft guideline on the conduct of efficacy studies for intramammary products for use in cattlehttps://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-efficacy-studies-intramammary-products-use-cattle_en.pdf-1Fri, 28 Jun 2024 13:00:00 +0200Public consultationsNilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidancehttps://www.ema.europa.eu/en/documents/scientific-guideline/nilotinib-hard-capsules-50-150-200-mg-product-specific-bioequivalence-guidance_en.pdfNilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidancehttps://www.ema.europa.eu/en/documents/scientific-guideline/nilotinib-hard-capsules-50-150-200-mg-product-specific-bioequivalence-guidance_en.pdfTue, 25 Jun 2024 15:05:36 +0200Public consultationsMethylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidancehttps://www.ema.europa.eu/en/documents/scientific-guideline/methylphenidate-prolonged-release-tablet-18-mg-27-mg-36-mg-54-mg-modified-release-capsule-5-mg-10-mg-20-mg-30-mg-40-mg-50-mg-60-mg-product-specific-bioequivalence-guidance_en.pdfMethylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidancehttps://www.ema.europa.eu/en/documents/scientific-guideline/methylphenidate-prolonged-release-tablet-18-mg-27-mg-36-mg-54-mg-modified-release-capsule-5-mg-10-mg-20-mg-30-mg-40-mg-50-mg-60-mg-product-specific-bioequivalence-guidance_en.pdfTue, 25 Jun 2024 15:03:13 +0200Public consultationsBudesonide, prolonged release tablets, 9 mg product-specific bioequivalence guidancehttps://www.ema.europa.eu/en/documents/scientific-guideline/budesonide-prolonged-release-tablets-9-mg-product-specific-bioequivalence-guidance_en.pdfBudesonide, prolonged release tablets, 9 mg product-specific bioequivalence guidancehttps://www.ema.europa.eu/en/documents/scientific-guideline/budesonide-prolonged-release-tablets-9-mg-product-specific-bioequivalence-guidance_en.pdfTue, 25 Jun 2024 08:00:00 +0200Public consultations